NASDAQ:IMMU - Immunomedics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$87.86
+0.30 (1.20%)
Get New Immunomedics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMU

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Immunomedics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $87.86.

This chart shows the closing price for IMMU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Immunomedics. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/16/2020BarclaysReiterated RatingHold$88.00Low
9/15/2020GuggenheimDowngradeBuy ➝ NeutralLow
9/15/2020Jefferies Financial GroupDowngradeBuy ➝ HoldLow
9/14/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
9/14/2020Wells Fargo & CompanyReiterated RatingOverweight ➝ Equal WeightN/A
8/10/2020Morgan StanleyBoost Price TargetEqual Weight$32.00 ➝ $40.00Low
8/6/2020HC WainwrightReiterated RatingBuy$56.00Low
8/6/2020Piper SandlerBoost Price TargetOverweight$55.00 ➝ $60.00Low
8/3/2020Bank of AmericaBoost Price TargetBuy$45.00 ➝ $47.00Low
7/27/2020Jefferies Financial GroupBoost Price TargetBuy$41.00 ➝ $55.00High
7/14/2020HC WainwrightReiterated RatingBuy$56.00High
7/7/2020GuggenheimBoost Price TargetBuy$48.00 ➝ $52.00High
7/7/2020HC WainwrightBoost Price TargetBuy$54.00 ➝ $56.00Medium
7/6/2020CowenReiterated RatingBuy$45.00Low
7/6/2020Piper SandlerBoost Price Target$40.00 ➝ $55.00Low
7/6/2020Wells Fargo & CompanyReiterated RatingBuy$41.00 ➝ $55.00Low
5/28/2020HC WainwrightReiterated RatingBuy$54.00High
5/7/2020Morgan StanleyBoost Price TargetEqual Weight$22.00 ➝ $32.00Low
5/7/2020HC WainwrightLower Price TargetBuy$60.00 ➝ $54.00Low
5/4/2020BarclaysInitiated CoverageOverweight$40.00Low
4/23/2020The Goldman Sachs GroupUpgradeSell ➝ Neutral$5.00 ➝ $22.00High
4/23/2020Wells Fargo & CompanyBoost Price TargetOverweight$34.00 ➝ $41.00High
4/23/2020GuggenheimBoost Price TargetPositive ➝ Buy$35.00 ➝ $39.00High
4/23/2020CowenBoost Price TargetOutperform$30.00 ➝ $45.00High
4/23/2020HC WainwrightBoost Price TargetBuy$34.00 ➝ $60.00High
4/22/2020Piper SandlerBoost Price TargetOverweight$30.00 ➝ $40.00High
4/15/2020Morgan StanleyBoost Price TargetEqual Weight$19.00 ➝ $22.00Low
4/8/2020HC WainwrightReiterated RatingBuy ➝ PositiveLow
4/7/2020HC WainwrightBoost Price TargetBuy ➝ Buy$31.00 ➝ $34.00Medium
4/6/2020Piper SandlerBoost Price Target$25.00 ➝ $30.00N/A
4/6/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$34.00N/A
4/3/2020The Goldman Sachs GroupDowngradeBuy ➝ Sell$24.00 ➝ $5.00High
3/3/2020Morgan StanleyBoost Price TargetEqual Weight$17.00 ➝ $19.00Medium
2/28/2020HC WainwrightReiterated RatingBuyLow
2/28/2020CowenReiterated RatingBuy$30.00High
12/27/2019HC WainwrightBoost Price TargetBuy$26.00 ➝ $31.00Medium
12/20/2019Bank of AmericaInitiated CoverageBuy$26.00High
12/3/2019CowenReiterated RatingBuy$30.00Low
12/3/2019HC WainwrightReiterated RatingBuy$26.00Low
11/6/2019Piper Jaffray CompaniesBoost Price TargetOverweight$20.00 ➝ $25.00Medium
10/31/2019HC WainwrightReiterated RatingBuy$26.00Medium
9/30/2019B. RileySet Price TargetBuy$28.00High
9/30/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$14.00 ➝ $16.00High
9/30/2019HC WainwrightReiterated RatingBuy$26.00High
9/29/2019CowenSet Price TargetBuy$30.00High
9/10/2019CowenSet Price TargetBuy$30.00High
9/10/2019Piper Jaffray CompaniesSet Price TargetBuy$20.00High
9/10/2019Jefferies Financial GroupSet Price TargetBuy$22.00High
8/19/2019Cantor FitzgeraldInitiated CoverageOverweight$28.00High
8/8/2019HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $26.00High
8/7/2019CowenSet Price TargetBuy$30.00Medium
7/31/2019CowenSet Price TargetBuy$30.00N/A
5/13/2019HC WainwrightReiterated RatingBuy$28.00Medium
4/30/2019HC WainwrightReiterated RatingBuy$29.00Medium
4/8/2019Piper Jaffray CompaniesSet Price TargetBuy$20.00Medium
4/2/2019HC WainwrightSet Price TargetBuy$28.00Low
3/27/2019Berenberg BankInitiated CoverageBuy ➝ Buy$40.00Medium
3/4/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00Low
1/23/2019B. RileySet Price TargetBuy$55.00 ➝ $28.00Medium
1/22/2019Piper Jaffray CompaniesLower Price TargetOverweight$20.00Medium
1/18/2019Jefferies Financial GroupSet Price TargetBuy$21.00Low
1/18/2019CowenReiterated RatingBuy$30.00High
1/18/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$44.00 ➝ $18.00High
1/8/2019B. RileyInitiated CoverageBuy$55.00High
12/23/2018Jefferies Financial GroupSet Price TargetBuy$30.00Low
12/20/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
12/7/2018CowenReiterated RatingBuy$30.00High
11/8/2018Jefferies Financial GroupInitiated CoverageBuy$30.00High
11/5/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$38.00Medium
10/18/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Buy$33.00High
10/17/2018Wells Fargo & CompanyBoost Price TargetOutperform$31.00 ➝ $44.00Medium
9/18/2018GuggenheimInitiated CoverageBuy$33.00Medium
9/17/2018The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$36.00Medium
8/24/2018B. RileyBoost Price TargetBuy ➝ Buy$53.00 ➝ $55.00Low
6/7/2018B. RileyInitiated CoverageBuy$53.00Medium
6/4/2018Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$25.00 ➝ $31.00High
1/24/2018Jefferies Financial GroupBoost Price TargetBuy$22.00 ➝ $27.00Medium
10/9/2017Jefferies Financial GroupBoost Price TargetBuy$14.00 ➝ $16.00N/A
9/19/2017Jefferies Financial GroupBoost Price TargetBuy$11.00 ➝ $14.00High
8/17/2017Jefferies Financial GroupSet Price TargetBuy$11.00High
7/24/2017CowenReiterated RatingOutperform$15.00Low
7/14/2017Jefferies Financial GroupReiterated RatingBuy$11.00Low
6/10/2017Jefferies Financial GroupSet Price TargetBuy$9.00High
5/26/2017CowenInitiated CoverageOutperformHigh
5/6/2017Jefferies Financial GroupSet Price TargetBuy$9.00High
5/5/2017Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
4/20/2017Jefferies Financial GroupSet Price TargetBuy$8.00Low
3/16/2017Jefferies Financial GroupSet Price TargetBuy$8.00High
3/6/2017Jefferies Financial GroupReiterated RatingBuy$7.50N/A
2/21/2017Jefferies Financial GroupReiterated RatingBuy$7.50N/A
10/6/2016Jefferies Financial GroupInitiated CoverageBuy$5.00 ➝ $5.50N/A
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Immunomedics logo
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Read More

Today's Range

Now: $87.86
Low: $87.86
High: $87.86

50 Day Range

MA: $87.41
Low: $85.08
High: $87.86

52 Week Range

Now: $87.86
Low: $8.80
High: $87.93

Volume

N/A

Average Volume

4,013,131 shs

Market Capitalization

$20.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunomedics?

The following Wall Street research analysts have issued stock ratings on Immunomedics in the last year:
View the latest analyst ratings for IMMU.

What is the current price target for Immunomedics?

0 Wall Street analysts have set twelve-month price targets for Immunomedics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Immunomedics in the next year.
View the latest price targets for IMMU.

What is the current consensus analyst rating for Immunomedics?

Immunomedics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMMU.

How do I contact Immunomedics' investor relations team?

Immunomedics' physical mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company's listed phone number is 973-605-8200 and its investor relations email address is [email protected] The official website for Immunomedics is www.immunomedics.com.